CN Patent

CN108138182A — 甲状腺素运载蛋白（TTR）iRNA组合物及其治疗或预防TTR相关疾病的使用方法

Assigned to Alnylam Pharmaceuticals Inc · Expires 2018-06-08 · 8y expired

What this patent protects

本发明提供靶向甲状腺素运载蛋白(TTR)基因的iRNA剂，例如，双链iRNA剂，以及使用此类iRNA剂用于治疗或预防TTR相关疾病的方法。

USPTO Abstract

本发明提供靶向甲状腺素运载蛋白(TTR)基因的iRNA剂，例如，双链iRNA剂，以及使用此类iRNA剂用于治疗或预防TTR相关疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN108138182A
Jurisdiction
CN
Classification
—
Expires
2018-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.